Company / Operating Cash Flow
Ernexa Therapeutics Inc. Operating Cash Flow History
FY2014-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Cash Flow
-$15.8M
FY2025
5-year range
-$21.0M / $2.7M
FY2021-FY2025
Trend
+22.4%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Operating Cash Flow has fluctuated over the past 10 years, ranging from -$21M in FY2023 to $3M in FY2020.
Based on SEC 10-K filings.
-$16M in FY2025.
Improved from -$21M to -$16M over the past 2 years.
Operating Cash Flow over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2025, operating cash flow increased 22.4% year-over-year.
- Peak operating cash flow was recorded in FY2020.
- Lowest operating cash flow in the period was in FY2023.
Company context
Key Data Points
- Altman Z-Score -8.07 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating Cash FlowValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$15.8M | +22.4% |
| FY2024 | -$20.4M | +2.7% |
| FY2023 | -$21.0M | -864.4% |
| FY2020 | $2.7M | +101.0% |
| FY2019 | $1.4M | +148.6% |
| FY2018 | $549.0K | +2287.0% |
| FY2017 | $23.0K | +100.6% |
| FY2016 | -$4.2M | +34.5% |
| FY2015 | -$6.4M | -466.7% |
| FY2014 | $1.7M | -19.2% |
As of FY2025 · SEC 10-K · Updated Jun 28, 2026